---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-000837"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:11:32.705140+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunocore reports ~$820M cash; three Phase 3 melanoma trials; new autoimmune candidate

## Summary
- Preliminary cash ~$820M as of Dec 31, 2024; Pharmakon loan prepaid in full.
- Three Phase 3 trials enrolling in melanoma (TEBE-AM, PRISM-MEL-301, ATOM); first topline data expected 2026.
- New autoimmune candidate IMC-U120AI (CD1a x PD1) for atopic dermatitis; CTA planned 2026.
- Initial HIV Phase 1 multiple ascending dose data for IMC-M113V expected Q1 2025.
- Travis Coy appointed EVP, CFO and Head of Corporate Development (ex-Eli Lilly).

## SEC filing metadata
- accession: 0001140361-25-000837
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036125000837/0001140361-25-000837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036125000837/ef20041400_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-000837
- JSON: https://secwatch.observer/filing/0001140361-25-000837.json
- Plain text: https://secwatch.observer/filing/0001140361-25-000837.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.